Outcomes of an underserved hispanic population with chronic hepatitis C treated with pegylated-interferon and ribavirin in a government-sponsored clinic

Puerto Rico Health Sciences Journal

Volumn 30, Issue 1, 2011, Pages 9-13

  Iturrino, Johanna ^a   Sánchez, Carlos J ^a   Ortiz, Adelaida ^a   Romero, Carlos J ^a   Velázquez, Vanessa ^a   Costas, Pablo ^a   Torres, Esther A ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Hepatitis C; Hispanics; Treatment response

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; FEMALE; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HEPATITIS C; HISPANIC; HUMAN; MALE; MIDDLE AGED; PUERTO RICO; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; GOVERNMENT PROGRAMS; HEALTH FACILITIES; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HUMANS; INTERFERON ALFA-2B; MALE; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; POLYETHYLENE GLYCOLS; PUERTO RICO; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951757014     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-65S.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
3. Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006;10:919-40.
4. Alter MJ, Kruzon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA,Kaslow RA, Margolis HS. The prevalence of hepatitis infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
5. Pérez CM, Suárez E, Torres EA, Román K, Colón V. Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico. Int J Epidemiol 2005;34:593-9.
6. Pérez CM, Marrero E, Meléndez M, et al. Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infectious Diseases 2010, 10:76 doi:10.1186/1471-2334-10-76.
7. Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A. More advanced hepatic fibrosis in Hispanic patients with chronic hepatitis C: role of patient demographics, hepatic necroinflammation and steatosis. Am J Gastroenterol 2006;101:1817-23.
8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
10. Hoofnagle, JH, and LB Seeff. 2006. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med2006;355:2444-51.
11. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
12. Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, Brau N, Wright TL. Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance and Outcomes. A J Gastroenterol 2005;100:2186-93.
13. Toro D, De Jesús JJ, et al. Peginterferon Alfa-2b and Ribavirin Treatment Response Among Hispanics with Chronic Hepatitis C Genotype 1. A J Gastroenterol 2005;100:S103-S144.
14. Rodríguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P. Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. N Engl J Med2009;360:257-67.
15. Costas P, Ortiz A, Velázquez V, Torres EA. A Government Sponsored Clinic for the Evaluation and Treatment of Chronic Hepatitis C in an Underinsured Population in Puerto Rico. P R Health Sci J 2004;23:41-7.